HC Wainwright Forecasts Curis’ Q1 Earnings (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Curis in a report issued on Friday, March 20th. HC Wainwright analyst S. Nik forecasts that the biotechnology company will post earnings per share of ($0.19) for the quarter. HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Curis’ current full-year earnings is ($7.12) per share. HC Wainwright also issued estimates for Curis’ Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.24) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $17.00.

Curis Trading Up 1.9%

CRIS opened at $0.77 on Monday. The business’s 50 day moving average is $0.98 and its 200-day moving average is $1.24. The stock has a market cap of $10.59 million, a PE ratio of -0.65 and a beta of 3.02. Curis has a twelve month low of $0.75 and a twelve month high of $3.13.

Curis (NASDAQ:CRIS) last posted its earnings results on Thursday, March 19th. The biotechnology company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $3.25 million.

Institutional Investors Weigh In On Curis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC boosted its position in shares of Curis by 71.8% during the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 10,586 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Curis in the 4th quarter worth approximately $26,000. Warberg Asset Management LLC bought a new stake in shares of Curis in the 3rd quarter worth approximately $73,000. Squarepoint Ops LLC lifted its stake in Curis by 17.9% during the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 8,973 shares during the last quarter. Finally, Focused Wealth Management Inc lifted its stake in Curis by 33.8% during the third quarter. Focused Wealth Management Inc now owns 79,199 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 19,995 shares during the last quarter. 29.97% of the stock is owned by institutional investors and hedge funds.

Curis News Summary

Here are the key news stories impacting Curis this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating with a $17.00 price target — a highly bullish analyst endorsement that can attract speculative buying given the large upside to the current price. Benzinga
• Positive Sentiment: Company and management continue to advance oncology programs: Curis is targeting full enrollment in its PCNSL registrational study within 12–18 months and is progressing a CLL proof‑of‑concept — milestones that would materially de‑risk and re‑rate the pipeline if achieved. Seeking Alpha
• Neutral Sentiment: Curis issued a fourth-quarter 2025 business update and hosted a conference call — useful for detail and guidance but neutral until management gives clear forward guidance or cash/runway updates. PR Newswire
• Neutral Sentiment: Multiple transcripts of the Q4 2025 earnings call are available (MSN/Yahoo/Seeking Alpha) for investors who want management color; transcripts themselves don’t change fundamentals but help interpret pipeline timelines. MSN Transcript
• Negative Sentiment: Q4 results missed expectations — EPS of ($0.50) missed consensus by $0.07 and revenue of $1.14M missed estimates (~$3.25M). The miss raises near‑term financing and execution risk for a small‑cap biotech with limited revenue. MarketBeat Earnings
• Negative Sentiment: Curis reported an update indicating a pause in the emavusertib trial for certain indications (AML/MDS) — any trial pause increases clinical risk and could delay value realization from that program. Investors should watch for details on reasons for the pause and the path to restart. TipRanks
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous/zero values and NaN changes — current published short interest figures do not present a reliable signal. Monitor official exchange short‑interest reports for clarity.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.